Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression ...

Bryan Johnson injected himself with ketamine, a hallucinogen favored by Elon Musk, for 15 days. He used a helmet from his ...

However, Johnson & Johnson has a 'savior' in its neuroscience portfolio, namely Spravato (esketamine), which is the NMDA receptor antagonist. Moreover, on January 21, 2025, the FDA approved ...

The pharmaceutical company Johnson & Johnson created the spray from esketamine, a more potent version of ketamine. Esketamine should only provide rapid relief from depression symptoms until other ...

Ketamine, a dissociative anesthetic, has carved itself a spot in the world of mental health care over the past two decades.

Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

After the rejection of Lykos Therapeutics’ MDMA-based PTSD treatment tempered excitement for psychedelic therapeutics, a ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...

The company announced on 18 February that the trial did not meet its primary endpoint measured by a depression rating scale, ...

Escalating concerns over impending tariffs and President Trump's foreign policies have fueled uncertainty and instability in ...

The Johnson & Johnson drug has been on the market ... what we can do is we can stop that antidepressant and initiate the esketamine, the Spravato, without continuing another drug,” said Dr ...

The U.S. FDA rejection of an MDMA-based drug from Lykos Therapeutics for PTSD in August 2024 has not dimmed hopes that other psychedelic-oriented therapies can gain approval, according to the CEO of ...